Global Information
회사소개 | 문의 | 비교리스트

코로나바이러스 백신 : 세계 시장 전망(2018-2027년)

Coronavirus Vaccine - Global Market Outlook (2018-2027)

리서치사 Stratistics Market Research Consulting
발행일 2020년 05월 상품 코드 939214
페이지 정보 영문 119 Pages
가격
US $ 4,150 ₩ 4,734,000 PDF (Single User License)
US $ 5,250 ₩ 5,989,000 PDF (2-5 User License)
US $ 6,350 ₩ 7,244,000 PDF (Site License)
US $ 7,500 ₩ 8,556,000 PDF (Global Site License)


코로나바이러스 백신 : 세계 시장 전망(2018-2027년) Coronavirus Vaccine - Global Market Outlook (2018-2027)
발행일 : 2020년 05월 페이지 정보 : 영문 119 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 코로나바이러스 백신 시장은 2018년에 1,869만 달러를 기록했습니다. 이 시장은 예측 기간 중 53.8%의 CAGR로 성장할 전망이며, 2027년에는 9억 14만 달러에 달할 것으로 예측되고 있습니다. 시장 성장을 촉진하는 주요 요인에는 세계의 바이러스 감염자 증가를 들 수 있습니다. 그러나 치료용 백신 및 치료제의 조사 개발에 드는 고비용, 임상시험의 각 단계에 필요한 시간 등은 시장 성장을 방해하는 요인입니다.

세계의 코로나바이러스 백신 시장에 대해 조사했으며, 시장 기회 및 동향, 성장 및 억제요인, 감염 유형·백신 유형·제품 유형·투여 경로·환자 유형·최종사용자·지역별 시장 분석, 경쟁 구도, 주요 기업의 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 개요

제2장 서론

제3장 시장 동향 분석

  • 서론
  • 성장요인
  • 억제요인
  • 시장 기회
  • 위협
  • 최종사용자 분석
  • 신흥 시장
  • 신종 코로나바이러스 감염증의 영향

제4장 Porter의 산업 분석

제5장 세계 시장 : 감염 유형별

  • 서론
  • HCoV-229E
  • HCoV-OC43
  • HKU1-CoV
  • MERS-CoV
  • New Haven CoV
  • SARS-CoV

제6장 세계 시장 : 백신 유형별

  • 서론
  • S-단백질 기반 코로나바이러스 백신
  • 약독생 코로나바이러스 백신
  • 불활성화 코로나바이러스 백신
  • mRNA 기반 백신
  • DNA 기반 백신

제7장 세계 시장 : 제품 유형

  • 서론
  • 일가백신 대 다가백신

제8장 세계 시장 : 투여 경로별

  • 서론
  • 피하
  • 구강
  • 근육내

제9장 세계 시장 : 환자 유형별

  • 서론
  • 소아
  • 성인

제10장 세계 시장 : 최종사용자별

  • 서론
  • 클리닉
  • 병원
  • 조사기관

제11장 세계 시장 : 지역별

  • 서론
  • 북미
  • 유럽
  • 아시아태평양
  • 남미
  • 중동·아프리카

제12장 주요 발전

  • 계약, 제휴, 협업, 합병사업
  • 인수합병
  • 신제품 발매
  • 확장
  • 기타 주요 전략

제13장 기업 개요

  • Inovio Pharmaceuticals, Inc.
  • Moderna, Inc.
  • Protein Potential, LLC
  • Novavax, Inc.
  • Synairgen PLC
  • AlphaVax, Inc.
  • NanoViricides, Inc.
  • Zydus Cadila
  • Bravovax
  • GeoVax
  • Altimmune
  • Janssen Pharmaceutical Companies
  • CanSino Biologics
  • Vaxart
  • Vaxil Bio Ltd
KSA 20.06.15

List of Tables

  • Table 1 Global Coronavirus Vaccine Market Outlook, By Region (2017-2027) ($MN)
  • Table 2 Global Coronavirus Vaccine Market Outlook, By Infection Type (2017-2027) ($MN)
  • Table 3 Global Coronavirus Vaccine Market Outlook, By HCoV-229E (2017-2027) ($MN)
  • Table 4 Global Coronavirus Vaccine Market Outlook, By HCoV-OC43 (2017-2027) ($MN)
  • Table 5 Global Coronavirus Vaccine Market Outlook, By HKU1-CoV (2017-2027) ($MN)
  • Table 6 Global Coronavirus Vaccine Market Outlook, By MERS-CoV (2017-2027) ($MN)
  • Table 7 Global Coronavirus Vaccine Market Outlook, By New Haven CoV (2017-2027) ($MN)
  • Table 8 Global Coronavirus Vaccine Market Outlook, By SARS-CoV (2017-2027) ($MN)
  • Table 9 Global Coronavirus Vaccine Market Outlook, By Vaccine Type (2017-2027) ($MN)
  • Table 10 Global Coronavirus Vaccine Market Outlook, By S-Protein Based Coronavirus Vaccine (2017-2027) ($MN)
  • Table 11 Global Coronavirus Vaccine Market Outlook, By Live Attenuated Coronavirus Vaccine (2017-2027) ($MN)
  • Table 12 Global Coronavirus Vaccine Market Outlook, By Inactivated Coronavirus Vaccine (2017-2027) ($MN)
  • Table 13 Global Coronavirus Vaccine Market Outlook, By mRNA Vaccine (2017-2027) ($MN)
  • Table 14 Global Coronavirus Vaccine Market Outlook, By DNA-Based Vaccine (2017-2027) ($MN)
  • Table 15 Global Coronavirus Vaccine Market Outlook, By Product Type (2017-2027) ($MN)
  • Table 16 Global Coronavirus Vaccine Market Outlook, By Monovalent Vaccine v/s Multivariant Vaccine (2017-2027) ($MN)
  • Table 17 Global Coronavirus Vaccine Market Outlook, By Route of Administration (2017-2027) ($MN)
  • Table 18 Global Coronavirus Vaccine Market Outlook, By Subcutaneous (2017-2027) ($MN)
  • Table 19 Global Coronavirus Vaccine Market Outlook, By Oral (2017-2027) ($MN)
  • Table 20 Global Coronavirus Vaccine Market Outlook, By Intramuscular (2017-2027) ($MN)
  • Table 21 Global Coronavirus Vaccine Market Outlook, By Patient Type (2017-2027) ($MN)
  • Table 22 Global Coronavirus Vaccine Market Outlook, By Pediatric (2017-2027) ($MN)
  • Table 23 Global Coronavirus Vaccine Market Outlook, By Adult (2017-2027) ($MN)
  • Table 24 Global Coronavirus Vaccine Market Outlook, By End User (2017-2027) ($MN)
  • Table 25 Global Coronavirus Vaccine Market Outlook, By Clinics (2017-2027) ($MN)
  • Table 26 Global Coronavirus Vaccine Market Outlook, By Hospitals (2017-2027) ($MN)
  • Table 27 Global Coronavirus Vaccine Market Outlook, By Research Institutes (2017-2027) ($MN)
  • Table 28 North America Coronavirus Vaccine Market Outlook, By Country (2017-2027) ($MN)
  • Table 29 North America Coronavirus Vaccine Market Outlook, By Infection Type (2017-2027) ($MN)
  • Table 30 North America Coronavirus Vaccine Market Outlook, By HCoV-229E (2017-2027) ($MN)
  • Table 31 North America Coronavirus Vaccine Market Outlook, By HCoV-OC43 (2017-2027) ($MN)
  • Table 32 North America Coronavirus Vaccine Market Outlook, By HKU1-CoV (2017-2027) ($MN)
  • Table 33 North America Coronavirus Vaccine Market Outlook, By MERS-CoV (2017-2027) ($MN)
  • Table 34 North America Coronavirus Vaccine Market Outlook, By New Haven CoV (2017-2027) ($MN)
  • Table 35 North America Coronavirus Vaccine Market Outlook, By SARS-CoV (2017-2027) ($MN)
  • Table 36 North America Coronavirus Vaccine Market Outlook, By Vaccine Type (2017-2027) ($MN)
  • Table 37 North America Coronavirus Vaccine Market Outlook, By S-Protein Based Coronavirus Vaccine (2017-2027) ($MN)
  • Table 38 North America Coronavirus Vaccine Market Outlook, By Live Attenuated Coronavirus Vaccine (2017-2027) ($MN)
  • Table 39 North America Coronavirus Vaccine Market Outlook, By Inactivated Coronavirus Vaccine (2017-2027) ($MN)
  • Table 40 North America Coronavirus Vaccine Market Outlook, By mRNA Vaccine (2017-2027) ($MN)
  • Table 41 North America Coronavirus Vaccine Market Outlook, By DNA-Based Vaccine (2017-2027) ($MN)
  • Table 42 North America Coronavirus Vaccine Market Outlook, By Product Type (2017-2027) ($MN)
  • Table 43 North America Coronavirus Vaccine Market Outlook, By Monovalent Vaccine v/s Multivariant Vaccine (2017-2027) ($MN)
  • Table 44 North America Coronavirus Vaccine Market Outlook, By Route of Administration (2017-2027) ($MN)
  • Table 45 North America Coronavirus Vaccine Market Outlook, By Subcutaneous (2017-2027) ($MN)
  • Table 46 North America Coronavirus Vaccine Market Outlook, By Oral (2017-2027) ($MN)
  • Table 47 North America Coronavirus Vaccine Market Outlook, By Intramuscular (2017-2027) ($MN)
  • Table 48 North America Coronavirus Vaccine Market Outlook, By Patient Type (2017-2027) ($MN)
  • Table 49 North America Coronavirus Vaccine Market Outlook, By Pediatric (2017-2027) ($MN)
  • Table 50 North America Coronavirus Vaccine Market Outlook, By Adult (2017-2027) ($MN)
  • Table 51 North America Coronavirus Vaccine Market Outlook, By End User (2017-2027) ($MN)
  • Table 52 North America Coronavirus Vaccine Market Outlook, By Clinics (2017-2027) ($MN)
  • Table 53 North America Coronavirus Vaccine Market Outlook, By Hospitals (2017-2027) ($MN)
  • Table 54 North America Coronavirus Vaccine Market Outlook, By Research Institutes (2017-2027) ($MN)
  • Table 55 Europe Coronavirus Vaccine Market Outlook, By Country (2017-2027) ($MN)
  • Table 56 Europe Coronavirus Vaccine Market Outlook, By Infection Type (2017-2027) ($MN)
  • Table 57 Europe Coronavirus Vaccine Market Outlook, By HCoV-229E (2017-2027) ($MN)
  • Table 58 Europe Coronavirus Vaccine Market Outlook, By HCoV-OC43 (2017-2027) ($MN)
  • Table 59 Europe Coronavirus Vaccine Market Outlook, By HKU1-CoV (2017-2027) ($MN)
  • Table 60 Europe Coronavirus Vaccine Market Outlook, By MERS-CoV (2017-2027) ($MN)
  • Table 61 Europe Coronavirus Vaccine Market Outlook, By New Haven CoV (2017-2027) ($MN)
  • Table 62 Europe Coronavirus Vaccine Market Outlook, By SARS-CoV (2017-2027) ($MN)
  • Table 63 Europe Coronavirus Vaccine Market Outlook, By Vaccine Type (2017-2027) ($MN)
  • Table 64 Europe Coronavirus Vaccine Market Outlook, By S-Protein Based Coronavirus Vaccine (2017-2027) ($MN)
  • Table 65 Europe Coronavirus Vaccine Market Outlook, By Live Attenuated Coronavirus Vaccine (2017-2027) ($MN)
  • Table 66 Europe Coronavirus Vaccine Market Outlook, By Inactivated Coronavirus Vaccine (2017-2027) ($MN)
  • Table 67 Europe Coronavirus Vaccine Market Outlook, By mRNA Vaccine (2017-2027) ($MN)
  • Table 68 Europe Coronavirus Vaccine Market Outlook, By DNA-Based Vaccine (2017-2027) ($MN)
  • Table 69 Europe Coronavirus Vaccine Market Outlook, By Product Type (2017-2027) ($MN)
  • Table 70 Europe Coronavirus Vaccine Market Outlook, By Monovalent Vaccine v/s Multivariant Vaccine (2017-2027) ($MN)
  • Table 71 Europe Coronavirus Vaccine Market Outlook, By Route of Administration (2017-2027) ($MN)
  • Table 72 Europe Coronavirus Vaccine Market Outlook, By Subcutaneous (2017-2027) ($MN)
  • Table 73 Europe Coronavirus Vaccine Market Outlook, By Oral (2017-2027) ($MN)
  • Table 74 Europe Coronavirus Vaccine Market Outlook, By Intramuscular (2017-2027) ($MN)
  • Table 75 Europe Coronavirus Vaccine Market Outlook, By Patient Type (2017-2027) ($MN)
  • Table 76 Europe Coronavirus Vaccine Market Outlook, By Pediatric (2017-2027) ($MN)
  • Table 77 Europe Coronavirus Vaccine Market Outlook, By Adult (2017-2027) ($MN)
  • Table 78 Europe Coronavirus Vaccine Market Outlook, By End User (2017-2027) ($MN)
  • Table 79 Europe Coronavirus Vaccine Market Outlook, By Clinics (2017-2027) ($MN)
  • Table 80 Europe Coronavirus Vaccine Market Outlook, By Hospitals (2017-2027) ($MN)
  • Table 81 Europe Coronavirus Vaccine Market Outlook, By Research Institutes (2017-2027) ($MN)
  • Table 82 Asia Pacific Coronavirus Vaccine Market Outlook, By Country (2017-2027) ($MN)
  • Table 83 Asia Pacific Coronavirus Vaccine Market Outlook, By Infection Type (2017-2027) ($MN)
  • Table 84 Asia Pacific Coronavirus Vaccine Market Outlook, By HCoV-229E (2017-2027) ($MN)
  • Table 85 Asia Pacific Coronavirus Vaccine Market Outlook, By HCoV-OC43 (2017-2027) ($MN)
  • Table 86 Asia Pacific Coronavirus Vaccine Market Outlook, By HKU1-CoV (2017-2027) ($MN)
  • Table 87 Asia Pacific Coronavirus Vaccine Market Outlook, By MERS-CoV (2017-2027) ($MN)
  • Table 88 Asia Pacific Coronavirus Vaccine Market Outlook, By New Haven CoV (2017-2027) ($MN)
  • Table 89 Asia Pacific Coronavirus Vaccine Market Outlook, By SARS-CoV (2017-2027) ($MN)
  • Table 90 Asia Pacific Coronavirus Vaccine Market Outlook, By Vaccine Type (2017-2027) ($MN)
  • Table 91 Asia Pacific Coronavirus Vaccine Market Outlook, By S-Protein Based Coronavirus Vaccine (2017-2027) ($MN)
  • Table 92 Asia Pacific Coronavirus Vaccine Market Outlook, By Live Attenuated Coronavirus Vaccine (2017-2027) ($MN)
  • Table 93 Asia Pacific Coronavirus Vaccine Market Outlook, By Inactivated Coronavirus Vaccine (2017-2027) ($MN)
  • Table 94 Asia Pacific Coronavirus Vaccine Market Outlook, By mRNA Vaccine (2017-2027) ($MN)
  • Table 95 Asia Pacific Coronavirus Vaccine Market Outlook, By DNA-Based Vaccine (2017-2027) ($MN)
  • Table 96 Asia Pacific Coronavirus Vaccine Market Outlook, By Product Type (2017-2027) ($MN)
  • Table 97 Asia Pacific Coronavirus Vaccine Market Outlook, By Monovalent Vaccine v/s Multivariant Vaccine (2017-2027) ($MN)
  • Table 98 Asia Pacific Coronavirus Vaccine Market Outlook, By Route of Administration (2017-2027) ($MN)
  • Table 99 Asia Pacific Coronavirus Vaccine Market Outlook, By Subcutaneous (2017-2027) ($MN)
  • Table 100 Asia Pacific Coronavirus Vaccine Market Outlook, By Oral (2017-2027) ($MN)
  • Table 101 Asia Pacific Coronavirus Vaccine Market Outlook, By Intramuscular (2017-2027) ($MN)
  • Table 102 Asia Pacific Coronavirus Vaccine Market Outlook, By Patient Type (2017-2027) ($MN)
  • Table 103 Asia Pacific Coronavirus Vaccine Market Outlook, By Pediatric (2017-2027) ($MN)
  • Table 104 Asia Pacific Coronavirus Vaccine Market Outlook, By Adult (2017-2027) ($MN)
  • Table 105 Asia Pacific Coronavirus Vaccine Market Outlook, By End User (2017-2027) ($MN)
  • Table 106 Asia Pacific Coronavirus Vaccine Market Outlook, By Clinics (2017-2027) ($MN)
  • Table 107 Asia Pacific Coronavirus Vaccine Market Outlook, By Hospitals (2017-2027) ($MN)
  • Table 108 Asia Pacific Coronavirus Vaccine Market Outlook, By Research Institutes (2017-2027) ($MN)
  • Table 109 South America Coronavirus Vaccine Market Outlook, By Country (2017-2027) ($MN)
  • Table 110 South America Coronavirus Vaccine Market Outlook, By Infection Type (2017-2027) ($MN)
  • Table 111 South America Coronavirus Vaccine Market Outlook, By HCoV-229E (2017-2027) ($MN)
  • Table 112 South America Coronavirus Vaccine Market Outlook, By HCoV-OC43 (2017-2027) ($MN)
  • Table 113 South America Coronavirus Vaccine Market Outlook, By HKU1-CoV (2017-2027) ($MN)
  • Table 114 South America Coronavirus Vaccine Market Outlook, By MERS-CoV (2017-2027) ($MN)
  • Table 115 South America Coronavirus Vaccine Market Outlook, By New Haven CoV (2017-2027) ($MN)
  • Table 116 South America Coronavirus Vaccine Market Outlook, By SARS-CoV (2017-2027) ($MN)
  • Table 117 South America Coronavirus Vaccine Market Outlook, By Vaccine Type (2017-2027) ($MN)
  • Table 118 South America Coronavirus Vaccine Market Outlook, By S-Protein Based Coronavirus Vaccine (2017-2027) ($MN)
  • Table 119 South America Coronavirus Vaccine Market Outlook, By Live Attenuated Coronavirus Vaccine (2017-2027) ($MN)
  • Table 120 South America Coronavirus Vaccine Market Outlook, By Inactivated Coronavirus Vaccine (2017-2027) ($MN)
  • Table 121 South America Coronavirus Vaccine Market Outlook, By mRNA Vaccine (2017-2027) ($MN)
  • Table 122 South America Coronavirus Vaccine Market Outlook, By DNA-Based Vaccine (2017-2027) ($MN)
  • Table 123 South America Coronavirus Vaccine Market Outlook, By Product Type (2017-2027) ($MN)
  • Table 124 South America Coronavirus Vaccine Market Outlook, By Monovalent Vaccine v/s Multivariant Vaccine (2017-2027) ($MN)
  • Table 125 South America Coronavirus Vaccine Market Outlook, By Route of Administration (2017-2027) ($MN)
  • Table 126 South America Coronavirus Vaccine Market Outlook, By Subcutaneous (2017-2027) ($MN)
  • Table 127 South America Coronavirus Vaccine Market Outlook, By Oral (2017-2027) ($MN)
  • Table 128 South America Coronavirus Vaccine Market Outlook, By Intramuscular (2017-2027) ($MN)
  • Table 129 South America Coronavirus Vaccine Market Outlook, By Patient Type (2017-2027) ($MN)
  • Table 130 South America Coronavirus Vaccine Market Outlook, By Pediatric (2017-2027) ($MN)
  • Table 131 South America Coronavirus Vaccine Market Outlook, By Adult (2017-2027) ($MN)
  • Table 132 South America Coronavirus Vaccine Market Outlook, By End User (2017-2027) ($MN)
  • Table 133 South America Coronavirus Vaccine Market Outlook, By Clinics (2017-2027) ($MN)
  • Table 134 South America Coronavirus Vaccine Market Outlook, By Hospitals (2017-2027) ($MN)
  • Table 135 South America Coronavirus Vaccine Market Outlook, By Research Institutes (2017-2027) ($MN)
  • Table 136 Middle East & Africa Coronavirus Vaccine Market Outlook, By Country (2017-2027) ($MN)
  • Table 137 Middle East & Africa Coronavirus Vaccine Market Outlook, By Infection Type (2017-2027) ($MN)
  • Table 138 Middle East & Africa Coronavirus Vaccine Market Outlook, By HCoV-229E (2017-2027) ($MN)
  • Table 139 Middle East & Africa Coronavirus Vaccine Market Outlook, By HCoV-OC43 (2017-2027) ($MN)
  • Table 140 Middle East & Africa Coronavirus Vaccine Market Outlook, By HKU1-CoV (2017-2027) ($MN)
  • Table 141 Middle East & Africa Coronavirus Vaccine Market Outlook, By MERS-CoV (2017-2027) ($MN)
  • Table 142 Middle East & Africa Coronavirus Vaccine Market Outlook, By New Haven CoV (2017-2027) ($MN)
  • Table 143 Middle East & Africa Coronavirus Vaccine Market Outlook, By SARS-CoV (2017-2027) ($MN)
  • Table 144 Middle East & Africa Coronavirus Vaccine Market Outlook, By Vaccine Type (2017-2027) ($MN)
  • Table 145 Middle East & Africa Coronavirus Vaccine Market Outlook, By S-Protein Based Coronavirus Vaccine (2017-2027) ($MN)
  • Table 146 Middle East & Africa Coronavirus Vaccine Market Outlook, By Live Attenuated Coronavirus Vaccine (2017-2027) ($MN)
  • Table 147 Middle East & Africa Coronavirus Vaccine Market Outlook, By Inactivated Coronavirus Vaccine (2017-2027) ($MN)
  • Table 148 Middle East & Africa Coronavirus Vaccine Market Outlook, By mRNA Vaccine (2017-2027) ($MN)
  • Table 149 Middle East & Africa Coronavirus Vaccine Market Outlook, By DNA-Based Vaccine (2017-2027) ($MN)
  • Table 150 Middle East & Africa Coronavirus Vaccine Market Outlook, By Product Type (2017-2027) ($MN)
  • Table 151 Middle East & Africa Coronavirus Vaccine Market Outlook, By Monovalent Vaccine v/s Multivariant Vaccine (2017-2027) ($MN)
  • Table 152 Middle East & Africa Coronavirus Vaccine Market Outlook, By Route of Administration (2017-2027) ($MN)
  • Table 153 Middle East & Africa Coronavirus Vaccine Market Outlook, By Subcutaneous (2017-2027) ($MN)
  • Table 154 Middle East & Africa Coronavirus Vaccine Market Outlook, By Oral (2017-2027) ($MN)
  • Table 155 Middle East & Africa Coronavirus Vaccine Market Outlook, By Intramuscular (2017-2027) ($MN)
  • Table 156 Middle East & Africa Coronavirus Vaccine Market Outlook, By Patient Type (2017-2027) ($MN)
  • Table 157 Middle East & Africa Coronavirus Vaccine Market Outlook, By Pediatric (2017-2027) ($MN)
  • Table 158 Middle East & Africa Coronavirus Vaccine Market Outlook, By Adult (2017-2027) ($MN)
  • Table 159 Middle East & Africa Coronavirus Vaccine Market Outlook, By End User (2017-2027) ($MN)
  • Table 160 Middle East & Africa Coronavirus Vaccine Market Outlook, By Clinics (2017-2027) ($MN)
  • Table 161 Middle East & Africa Coronavirus Vaccine Market Outlook, By Hospitals (2017-2027) ($MN)
  • Table 162 Middle East & Africa Coronavirus Vaccine Market Outlook, By Research Institutes (2017-2027) ($MN)

According to Stratistics MRC, the Global Coronavirus Vaccine Market is accounted for $18.69 million in 2018 and is expected to reach $900.14 million by 2027 growing at a CAGR of 53.8% during the forecast period. The increasing prevalence of virus infected people across the world is anticipated to drive the growth of the market. However, factors such as high cost involved in research and development of therapeutic vaccines and drugs, and time required for each stage of clinical trials are hampering the market growth.

Corona viruses are a group of viruses which cause diseases or infections in mammals as well as birds. Coronaviruses belong to the Coronaviridae or Torovirinae subfamily. Symptoms caused by these viruses include common cold to serious infections, pneumonia, strict respiratory complications, even kidney failure, and death. These symptoms are common among persons with a weak immune system, individuals with cardiopulmonary disease, infants, and elderly people.

Based on the vaccine type, the DNA-based vaccine segment is going to have a lucrative growth during the forecast period the technological advancements in the field of pharmaceutical industry have resulted in development of various effective type of vaccines such as DNA-based nucleic acid vaccines. The use of these vaccines on human body leads to development of anti-gen. Thus, the effectiveness of the vaccine against the virus is enhanced significantly.

By geography, Europe is likely to have a huge demand due to diverse coronavirus outbreaks in the current past and presence of major players in countries in the region. As well, rising investments in R&D activities, along with strong support from the government is driving the growth of the target market in this region.

Some of the key players profiled in the Coronavirus Vaccine Market include Inovio Pharmaceuticals, Inc., Moderna, Inc., Protein Potential, LLC, Novavax, Inc., Synairgen PLC, AlphaVax, Inc., NanoViricides, Inc., Zydus Cadila, Bravovax, GeoVax, Altimmune, Janssen Pharmaceutical Companies, CanSino Biologics, Vaxart and Vaxil Bio Ltd.

Infection Types Covered:

  • HCoV-229E
  • HCoV-OC43
  • HKU1-CoV
  • MERS-CoV
  • New Haven CoV
  • SARS-CoV

Vaccine Types Covered:

  • S-Protein Based Coronavirus Vaccine
  • Live Attenuated Coronavirus Vaccine
  • Inactivated Coronavirus Vaccine
  • mRNA Vaccine
  • DNA-Based Vaccine

Product Types Covered:

  • Monovalent Vaccine v/s Multivariant Vaccine

Route of Administrations Covered:

  • Subcutaneous
  • Oral
  • Intramuscular

Patient Types Covered:

  • Pediatric
  • Adult

End Users Covered:

  • Clinics
  • Hospitals
  • Research Institutes

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2017, 2018, 2019, 2023 and 2027
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Coronavirus Vaccine Market, By Infection Type

  • 5.1 Introduction
  • 5.2 HCoV-229E
  • 5.3 HCoV-OC43
  • 5.4 HKU1-CoV
  • 5.5 MERS-CoV
  • 5.6 New Haven CoV
  • 5.7 SARS-CoV

6 Global Coronavirus Vaccine Market, By Vaccine Type

  • 6.1 Introduction
  • 6.2 S-Protein Based Coronavirus Vaccine
  • 6.3 Live Attenuated Coronavirus Vaccine
  • 6.4 Inactivated Coronavirus Vaccine
  • 6.5 mRNA Vaccine
  • 6.6 DNA-Based Vaccine

7 Global Coronavirus Vaccine Market, By Product Type

  • 7.1 Introduction
  • 7.2 Monovalent Vaccine v/s Multivariant Vaccine

8 Global Coronavirus Vaccine Market, By Route of Administration

  • 8.1 Introduction
  • 8.2 Subcutaneous
  • 8.3 Oral
  • 8.4 Intramuscular

9 Global Coronavirus Vaccine Market, By Patient Type

  • 9.1 Introduction
  • 9.2 Pediatric
  • 9.3 Adult

10 Global Coronavirus Vaccine Market, By End User

  • 10.1 Introduction
  • 10.2 Clinics
  • 10.3 Hospitals
  • 10.4 Research Institutes

11 Global Coronavirus Vaccine Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Inovio Pharmaceuticals, Inc.
  • 13.2 Moderna, Inc.
  • 13.3 Protein Potential, LLC
  • 13.4 Novavax, Inc.
  • 13.5 Synairgen PLC
  • 13.6 AlphaVax, Inc.
  • 13.7 NanoViricides, Inc.
  • 13.8 Zydus Cadila
  • 13.9 Bravovax
  • 13.10 GeoVax
  • 13.11 Altimmune
  • 13.12 Janssen Pharmaceutical Companies
  • 13.13 CanSino Biologics
  • 13.14 Vaxart
  • 13.15 Vaxil Bio Ltd
Back to Top
전화 문의
F A Q